NEW YORK (GenomeWeb News) – Becton Dickinson today announced that it has received US Food and Drug Administration clearance to market its new assay for detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus DNA directly from nasal swabs.

The BD Max StaphSR Assay is for use on the BD Max System, a fully automated molecular diagnostic platform, and can detect mecA dropout mutants and other new strains of MRSA that may not be detected by other assays, said BD.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.